Hoşgören-Tekin, Selcen
Eyüboğlu, İrem Peker
Akkiprik, Mustafa
Giménez-Arnau, Ana Maria
Salman, Andaç
Funding for this research was provided by:
Acibadem Mehmet Ali Aydinlar University
Article History
Received: 26 February 2024
Revised: 20 April 2024
Accepted: 26 April 2024
First Online: 25 May 2024
Declarations
:
: The study was approved by Marmara University School of Medicine’s ethics committee (Approval number: 09.2021.10).
: SHT, IE, MA declare no conflict of interest. AS reports personal fees from Novartis, Sanofi and İbrahim Etem-Menarini, outside the submitted work. AGA recently was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient Pharmaceutials, Genentech, GSK, Instituto Carlos III- FEDER, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Novartis, Sanofi–Regeneron, Servier, Thermo Fisher Scientific, Uriach Pharma / Neucor.